Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis

American Heart Journal

Volumn 145, Issue 2, 2003, Pages 190-194

  Sullivan, Jerome L ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; IRON;

ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; HEALTH HAZARD; HEART DISEASE; HEART INFARCTION PREVENTION; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; HYPOTHESIS; IRON DEPLETION; ISCHEMIC HEART DISEASE; MENSTRUATION; NONHUMAN; OVARY FUNCTION; POSTMENOPAUSE; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0037326156     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.142     Document Type: Editorial

References (42)

1. Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974;49:476-88.
2. Hill JS, Hayden MR, Frohlich J, et al. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991;11:290-7.
3. Manson JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34-40.
4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
5. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. Ann Intern Med 1999;131:463-6.
6. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
7. Lenfant C. Preliminary trends in the Women's Health Initiative [press release]. NHLBI Communications Office; April 3, 2000.
8. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995;311:1193-6.
9. Ritterband AB, Jaffe IA, Densen PM, et al. Gonadal function and the development of coronary heart disease. Circulation 1963;27:237-51.
10. Kannel WB, Hjortland MC, McNamara PM, et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-52.
11. Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease: the Framingham Study. Ann Intern Med 1978; 89:157-61.
12. Punnonen R, Ikalainen M, Seppala E. Premenopausal hysterectomy and risk of cardiovascular disease. Lancet 1987;1:1139.
13. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
14. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1981;1:1293-4.
15. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989;117:1177-88.
16. Sullivan JL. Iron versus cholesterol - perspectives on the iron and heart disease debate. J Clin Epidemiol 1996;49:1345-52.
17. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
18. Meyers DG, Strickland D, Maloley PA, et al. Possible association of a reduction in cardiovascular events with blood donation. Heart 1997;78:188-93.
19. de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542-8.
20. Zacharski LR, Chow B, Lavori PW, et al. The iron (Fe) and atherosclerosis study (FeAST): pilot study of reduction of body iron stores in atherosclerotic peripheral vascular disease. Am Heart J 2000;139:337-45.
21. Lee TS, Shiao MS, Pan CC, et al. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation 1999;99:1222-9.
22. Ponraj D, Makjanic J, Thong PS, et al. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett 1999;459:218-22.
23. Kiechl S, Willeit J, Egger G, et al. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997;96:3300-7.
24. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med 1999;4:93-9.
25. van Jaarsveld H, Pool GF. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 2002;161:395-402.
26. Choi W, Pai H, Kim K, et al. Iron deficiency anemia increases nitric oxide production in healthy adolescents. Ann Hematol 2002; 81:1-6.
27. Ni Z, Morcos S, Vaziri ND. Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int 1997;52:195-201.
28. Rooyakkers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002;32(1 Suppl):9-16.
29. Kramer JH, Lightfoot FG, Weglicki WB. Cardiac tissue iron: effects on post-ischemic function and free radical production, and its possible role during preconditioning. Cell Mol Biol 2000;46:1313-27.
30. Nitenberg A, Ledoux S, Valensi P, et al. Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients. Diabetes 2002;51:813-8.
31. Duffy SJ, Biegelsen ES, Holbrook M, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001;103:2799-804.
32. Sullivan JL. Stored iron and myocardial perfusion deficits. Am Heart J 2002;143:193-5.
33. Say AE, Gursurer M, Yazicioglu MV, et al. Impact of body iron status on myocardial perfusion, left ventricular function, and angiographic morphologic features in patients with hypercholesterolemia. Am Heart J 2002;143:257-64.
34. Visseren FL, Verkerk MS, van Der BT, et al. Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest 2002;32(1 Suppl):84-90.
35. Kotamraju S, Chitambar CR, Kalivendi SV, et al. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells - role of oxidant-induced iron signaling in apoptosis. J Biol Chem 2002;277:17179-87.
36. Sullivan, JL. Misconceptions in the debate on the iron hypothesis. J Nutr Biochem 2001;12:33-7.
37. Ascherio A, Rimm EB, Giovannucci E, et al. Blood donations and risk of coronary heart disease in men. Circulation 2001;103:52-7.
38. Tuomainen TP, Salonen R, Nyyssonen K, et al. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland. BMJ 1997;314:793-4.
39. Meyers DG, Jensen KC, Menitove JE. Blood donation is associated with lower risk of cardiovascular events. Transfusion 2001;41:35S.
40. Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991;337:833-4.
41. Ginsburg J, Hardiman P, Okolo S. Postmenopausal estrogen and cardioprotection. Lancet 1991;337:1161-2.
42. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.